| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10016573 | HBV | ENSG00000102468.11 | protein_coding | HTR2A | No | No | 3356 | P28223 |
| TVIS44041305 | HTLV-1 | ENSG00000102468.11 | protein_coding | HTR2A | No | No | 3356 | P28223 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | HTR2A |
|---|---|
| DrugBank ID | DB01624 |
| Drug Name | Zuclopenthixol |
| Target ID | BE0000451 |
| UniProt ID | P28223 |
| Regulation Type | antagonist |
| PubMed IDs | 8748043; 19644682; 12957216 |
| Citations | Nyberg S, Farde L, Bartfai A, Halldin C: Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans. Int Clin Psychopharmacol. 1995 Nov;10(4):221-7.@@Gjerden P, Slordal L, Bramness JG: Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents. Eur J Clin Pharmacol. 2009 Dec;65(12):1229-35. doi: 10.1007/s00228-009-0696-6.@@Khalifa AE: Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms. Pharmacol Biochem Behav. 2003 Jul;75(4):755-62. |
| Groups | Approved; Investigational |
| Direct Classification | Thioxanthenes |
| SMILES | OCCN1CCN(CCC=C2C3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3)CC1 |
| Pathways | |
| PharmGKB | PA452629 |
| ChEMBL | CHEMBL53904 |
